PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Combination therapy – Market size and forecast 2018-2023
• Monotherapy – Market size and forecast 2018-2023
• Market opportunity by type
PART 07: MARKET SEGMENTATION BY PRODUCT
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Advances in diagnostic testing for HIV
• R&D of regenerative therapies
• Increasing R&D of HIV vaccines
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Johnson & Johnson Services Inc.
• Lupin Ltd.
• Merck & Co., Inc.
• Mylan NV
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of the global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Combination therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Combination therapy – Year-over-year growth 2019-2023 (%)
Exhibit 22: Monotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Monotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Market segmentation by product: overview
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AbbVie Inc. – Vendor overview
Exhibit 50: AbbVie Inc. – Business segments
Exhibit 51: AbbVie Inc. – Organizational developments
Exhibit 52: AbbVie Inc. – Geographic focus
Exhibit 53: AbbVie Inc. – Key offerings
Exhibit 54: AbbVie Inc. – Key customers
Exhibit 55: Boehringer Ingelheim International GmbH – Vendor overview
Exhibit 56: Boehringer Ingelheim International GmbH – Business segments
Exhibit 57: Boehringer Ingelheim International GmbH – Organizational developments
Exhibit 58: Boehringer Ingelheim International GmbH – Geographic focus
Exhibit 59: Boehringer Ingelheim International GmbH – Segment focus
Exhibit 60: Boehringer Ingelheim International GmbH – Key offerings
Exhibit 61: Boehringer Ingelheim International GmbH – Key customers
Exhibit 62: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 63: Bristol-Myers Squibb Co. – Business segments
Exhibit 64: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 65: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 66: Bristol-Myers Squibb Co. – Key offerings
Exhibit 67: Bristol-Myers Squibb Co. – Key customers
Exhibit 68: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 69: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 70: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 71: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 72: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 73: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 74: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 75: Gilead Sciences Inc. – Vendor overview
Exhibit 76: Gilead Sciences Inc. – Business segments
Exhibit 77: Gilead Sciences Inc. – Organizational developments
Exhibit 78: Gilead Sciences Inc. – Geographic focus
Exhibit 79: Gilead Sciences Inc. – Key offerings
Exhibit 80: Gilead Sciences Inc. – Key customers
Exhibit 81: GlaxoSmithKline Plc – Vendor overview
Exhibit 82: GlaxoSmithKline Plc – Business segments
Exhibit 83: GlaxoSmithKline Plc – Organizational developments
Exhibit 84: GlaxoSmithKline Plc – Geographic focus
Exhibit 85: GlaxoSmithKline Plc – Segment focus
Exhibit 86: GlaxoSmithKline Plc – Key offerings
Exhibit 87: GlaxoSmithKline Plc – Key customers
Exhibit 88: Johnson & Johnson Services, Inc. – Vendor overview
Exhibit 89: Johnson & Johnson Services, Inc. – Business segments
Exhibit 90: Johnson & Johnson Services, Inc. – Organizational developments
Exhibit 91: Johnson & Johnson Services, Inc. – Geographic focus
Exhibit 92: Johnson & Johnson Services, Inc. – Segment focus
Exhibit 93: Johnson & Johnson Services, Inc. – Key offerings
Exhibit 94: Johnson & Johnson Services, Inc. – Key customers
Exhibit 95: Lupin Ltd. – Vendor overview
Exhibit 96: Lupin Ltd. – Business segments
Exhibit 97: Lupin Ltd. – Organizational developments
Exhibit 98: Lupin Ltd. – Geographic focus
Exhibit 99: Lupin Ltd. – Key offerings
Exhibit 100: Lupin Ltd. – Key customers
Exhibit 101: Merck & Co. Inc. – Vendor overview
Exhibit 102: Merck & Co. Inc. – Business segments
Exhibit 103: Merck & Co. Inc. – Organizational developments
Exhibit 104: Merck & Co. Inc. – Geographic focus
Exhibit 105: Merck & Co. Inc. – Segment focus
Exhibit 106: Merck & Co. Inc. – Key offerings
Exhibit 107: Merck & Co. Inc. – Key customers
Exhibit 108: Mylan NV – Vendor overview
Exhibit 109: Mylan NV – Product segments
Exhibit 110: Mylan NV – Organizational developments
Exhibit 111: Mylan NV – Geographic focus
Exhibit 112: Mylan NV – Segment focus
Exhibit 113: Mylan NV – Key offerings
Exhibit 114: Mylan NV – Key customers
Exhibit 115: Pfizer Inc. – Vendor overview
Exhibit 116: Pfizer Inc. – Business segments
Exhibit 117: Pfizer Inc. – Organizational developments
Exhibit 118: Pfizer Inc. – Geographic focus
Exhibit 119: Pfizer Inc. – Segment focus
Exhibit 120: Pfizer Inc. – Key offerings
Exhibit 121: Pfizer Inc. – Key customers
Exhibit 122: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 123: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 124: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 125: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 126: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 127: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 128: Validation techniques employed for market sizing
Exhibit 129: Definition of market positioning of vendors
【掲載企業】
AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
【免責事項】
https://www.marketreport.jp/reports-disclaimer